pegenzileukin for t-cell dysfunction
Published 1 year ago • 136 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
2:41
cell avidity as a predictor of t-cell efficacy
-
2:48
the novel icaht grading system to predict toxicity following car t-cell therapy
-
1:23
the current treatment landscape for patients with t-cell prolymphocytic leukemia
-
3:51
skewed primary antigen-specific responses and chromatin remodelling of t-cells
-
0:52
mils as a source of t-cells for adoptive cellular therapy
-
3:18
granulocytes & t-cells as biomarkers for relapse in cml following discontinuation of tkis
-
12:51
haplogroup map of the world: your genetic surname ( download link)
-
21:38
drawing the line: the rationale behind blood tube collection order
-
5:42
promising therapeutic efficacy of ebv-specific t-cell immunotherapy tabelecleucel in ptld
-
8:57
outcomes of sct in t-all and t-lbl
-
2:11
the t-cell lymphoma project: prospective data collection changing the world
-
1:46
preclinical efficacy of the pkcβ inhibitor ms-553 in btki resistant cll
-
1:39
germline predisposition to clonal hematopoiesis and its role in leukemia progression
-
1:02
the use of car-t cell products in a real-world setting
-
2:59
clinical trials and novel agents under investigation in t-cell lymphoma
-
0:57
zamtocabtagene autoleucel: mechanism of production & potential implications for access
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:24
sequencing of btk inhibitors in cll
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
3:37
progress in the categorization and treatment of lr-mds
-
1:12
insights into the optimal management of cll: the importance of patient characteristics